Patents Examined by Tiffany Nicole Grooms
  • Patent number: 11486010
    Abstract: The present disclosure relates to high-throughput detection of polyketides using genetically encoded biosensors.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: November 1, 2022
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Gavin J. Williams, Christian Kasey, Yiwei Li
  • Patent number: 11479794
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: October 25, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11479793
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 25, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Patent number: 11473108
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: October 18, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11434262
    Abstract: Provided herein are compositions, kits and methods useful in the construction of designer transcription activator-like effector (dTALE) polypeptides.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: September 6, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Sriram Kosuri, George M. Church
  • Patent number: 11414653
    Abstract: The present invention provides for an Aspergillus niger host cell comprising a gene of interest operatively linked to an ecm33 promoter of an ascomycete fungi, wherein the gene of interest is heterologous to the ecm33 promoter and/or to Aspergillus niger. In some embodiments, the gene of interest is a glycoside hydrolase enzyme. In some embodiments, the glycoside hydrolase enzyme is a glucosidase.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: August 16, 2022
    Assignees: National Technology & Engineering Solutions of Sandia, LLC, Battelle Memorial Institute, The Regents of the University of California
    Inventors: John M. Gladden, Saori Amaike Campen, Jinxiang Zhang, Jon K. Magnuson, Scott E. Baker, Blake A. Simmons
  • Patent number: 11401532
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 2, 2022
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 11401522
    Abstract: Compositions and methods are provided for genome modification at a target site in the genome of a fungal cell. The methods and compositions are drawn to a guide polynucleotide/Cas endonuclease system for promoting modification of the DNA sequence at a target site in a fungal host cell genome.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 2, 2022
    Assignee: DANISCO US INC
    Inventors: Benjamin S. Bower, Jimmy Chan, Jing Ge, Xiaogang Gu, Susan Mampusti Madrid, Danfeng Song, Mingmin Song, Michael Ward, Steven Sungin Kim
  • Patent number: 11390908
    Abstract: A C9orf72 DNA repeat expansion can be detected using a CRISPR Arrayed Repeat Detection System (CARDS). Based upon the compositions and methods supporting this platform primary cell cultures and/or blood cell smears can be tested under conventional clinical diagnostic laboratory conditions to diagnose genetically-based diseases having DNA repeat expansions, including but not limited to ALS. dCas9 constructs are also contemplated as having fluorescent proteins bound to any or all stem loop sequences, wherein detection of a plurality of dCas9 constructs having different colored fluorescent proteins can simultaneously detect at least six (6) different gene target loci.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 19, 2022
    Assignees: UNIVERSITY OF MASSACHUSETTS, UNIVERSITY OF CENTRAL FLORIDA FOUNDATION, INC.
    Inventors: Thoru Pederson, Hanhui Ma, Li-Chun Tu, Ardalan Naseri, Maximilaan Huisman, Shaojie Zhang
  • Patent number: 11390886
    Abstract: The present invention discloses a system for targeted gene editing and related uses.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 19, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Shengkan Jin, Juan-Carlos Collantes
  • Patent number: 11365437
    Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 21, 2022
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
  • Patent number: 11345920
    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule as a medicament, as a vaccine or in gene therapy.
    Type: Grant
    Filed: December 5, 2021
    Date of Patent: May 31, 2022
    Assignee: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Stefanie Grund
  • Patent number: 11345933
    Abstract: Described herein are synthetic oligonucleotides for editing a cell. The oligonucleotides described herein comprise the following covalently-linked components: (i) a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 31, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Andrew Garst, Ryan T Gill
  • Patent number: 11312968
    Abstract: Strains of yeast genetically engineered to produce increased amounts of non-hydroxylated collagen or hydroxylated collagen are described. An all-in-one vector including the DNA necessary to produce collagen, promotors, and hydroxylating enzymes is also described. Methods for producing non-hydroxylated or hydroxylated collagen are also provided.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: April 26, 2022
    Assignee: MODERN MEADOW, INC.
    Inventors: Lixin Dai, Julia Borden, Jeffrey Nelson, Kristin Ruebling-Jass
  • Patent number: 11293029
    Abstract: Provided are native promoters comprising polynucleotides isolated from Corynebacterium glutamicum, and mutant promoters derived therefrom, which may be used to regulate, i.e., either increase or decrease, gene expression. Also provided are promoter ladders comprising a plurality of the promoters having incrementally increasing promoter activity. Also provided are host cells and recombinant vectors comprising the promoters, and methods of expressing genes of interest and producing biomolecules using the host cells.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: April 5, 2022
    Assignee: Zymergen Inc.
    Inventors: Zachariah Serber, Katherine G. Gora, Shawn P. Manchester
  • Patent number: 11286468
    Abstract: Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: March 29, 2022
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver
  • Patent number: 11254918
    Abstract: Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 22, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Novome Biotechnolooies, Inc.
    Inventors: Justin L. Sonnenburg, Weston R. Whitaker, Elizabeth Stanley, William C. DeLoache
  • Patent number: 11203620
    Abstract: The present invention provides a modified eukaryotic cell wherein the modified eukaryotic cell is not able to provide an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like gene.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: December 21, 2021
    Assignee: Novartis AG
    Inventors: Clemens Achm├╝ller, Ferdinand Zepeck, Franz Hartner, Thomas Specht
  • Patent number: 11198879
    Abstract: The present invention provides novel reagents and a cloning procedure based on homologous recombination for the site-directed cloning of a DNA fragment to a vector at designed site(s). The cloning reagents are made of mixture of extracts from at least two different cell types, preferably a mixture made of extracts from wild-type E. coli and S. cerevisiae. Due to the activity of the mixture of cell extracts, recombination occurs between the 3? and 5?-ends of the target DNA and at the ends of linearized vector, which facilitates in-frame construction of expression vectors.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 14, 2021
    Assignee: VIET NAM NATIONAL UNIVERSITY HO CHI MINH CITY
    Inventors: Phuong Thao Thi Dang, My Trinh Thi Nguyen, Nghia Hieu Nguyen, Thuoc Linh Tran
  • Patent number: 11180791
    Abstract: Products and methods for assessing the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain are provided. More specifically, methods for the assessment of the predisposition of a subject to develop an injury-induced chronic mechanical pain and/or an inflammatory-induced chronic thermal pain using the MYO1A gene as a biomarker and methods of treating selected subjects are provided.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: November 23, 2021
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventor: Abdelaziz Moqrich